Michael N. Neely, MD

Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on antiviral, antiretroviral and antifungal compounds, he has experience with other therapeutic areas. He is currently board certified in Pediatrics and Pediatric Infectious Diseases, and he is the co-Director of the Laboratory of Applied Pharmacokinetics in the University of Southern California (USC) Keck School of Medicine, working with multidisciplinary faculty collaborators in the Departments of Pediatrics, Medicine, and Preventive Medicine, in the Schools of Pharmacy and Mathematics, and the Jet Propulsion Laboratory in Pasadena, CA. With expertise in computerized drug-response modeling, he is applying his research interests to the care of his patients by operating the first HIV therapeutic drug management service at LAC+USC, which is available to all HIV providers. He also provides out- and inpatient pharmacologic consultation for a wide range of therapeutically challenging cases. In the fall of 2010, he will complete a Master’s of Science program in Clinical and Biomedical Investigations at USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling, and he has recently been appointed to the United States Food and Drug Administration Anti-infective Drug Advisory Committee. He has received NIH funding for most of his post-doctoral career, is the author of numerous papers and abstracts, and he is invited to give talks and workshops on dose individualization and optimization worldwide.

• Modeling Pharmacokinetics in Individual Patients Using Therapeutic Drug Monitoring and Artificial Population Quasi-Models: A Study with Piperacillin Pharmaceutics. 2024 Mar 04; 16(3). . View in PubMed
• Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity Clin Transl Sci. 2024 Mar; 17(3):e13764. . View in PubMed
• Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence Microbiol Spectr. 2024 Feb 06; 12(2):e0322223. . View in PubMed
• Training the next generation of pharmacometric modelers: a multisector perspective J Pharmacokinet Pharmacodyn. 2024 Feb; 51(1):5-31. . View in PubMed
• Correction to: Training the next generation of pharmacometric modelers: a multisector perspective J Pharmacokinet Pharmacodyn. 2024 Feb; 51(1):89. . View in PubMed
• Association of piperacillin and vancomycin exposure on acute kidney injury during combination therapy JAC Antimicrob Resist. 2024 Feb; 6(1):dlad157. . View in PubMed
• Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III) J Pediatric Infect Dis Soc. 2023 Jun 30; 12(6):334-341. . View in PubMed
• Optimizing Vancomycin Therapy in Critically Ill Children: A Population Pharmacokinetics Study to Inform Vancomycin Area under the Curve Estimation Using Novel Biomarkers Pharmaceutics. 2023 Apr 25; 15(5). . View in PubMed
• Variation in Treatment of Pediatric Tuberculosis Infection in Different Provider Settings J Pediatr. 2023 08; 259:113419. . View in PubMed
• A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization J Pharmacokinet Pharmacodyn. 2023 02; 50(1):33-43. . View in PubMed
• Model-Informed Rationale for Early Therapeutic Drug Monitoring of Colistin in Critically Ill Patients J Clin Pharmacol. 2023 01; 63(1):57-65. . View in PubMed
• Individual meropenem epithelial lining fluid and plasma PK/PD target attainment Antimicrob Agents Chemother. 2023 12 14; 67(12):e0072723. . View in PubMed
• Intravenous N-Acetylcysteine to Prevent Cisplatin-Induced Hearing Loss in Children: A Nonrandomized Controlled Phase I Trial Clin Cancer Res. 2023 07 05; 29(13):2410-2418. . View in PubMed
• Isavuconazole Pharmacokinetics and Pharmacodynamics in Children Pharmaceutics. 2022 Dec 26; 15(1). . View in PubMed
• Interchangeability of generic drugs for subpopulations: Bioequivalence simulation from a nonparametric PK model of gabapentin generic drugs Br J Clin Pharmacol. 2022 Dec 08. . View in PubMed
• Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings J Antimicrob Chemother. 2022 Nov 28; 77(12):3349-3357. . View in PubMed
• Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Compliant) J Clin Med. 2022 Jul 16; 11(14). . View in PubMed
• Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid Int J Antimicrob Agents. 2022 Feb; 59(2):106509. . View in PubMed
• Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts’ Discussion on Use, Strengths, and Limitations J Clin Pharmacol. 2022 02; 62(2):158-170. . View in PubMed
• Nonparametric Methods in Population Pharmacokinetics J Clin Pharmacol. 2022 02; 62(2):142-157. . View in PubMed
• Parental Perspectives on Immunizations: Impact of the COVID-19 Pandemic on Childhood Vaccine Hesitancy J Community Health. 2022 02; 47(1):39-52. . View in PubMed
• Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance J Antimicrob Chemother. 2022 04 27; 77(5):1334-1343. . View in PubMed
• Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Ther Drug Monit. 2022 02 01; 44(1):121-132. . View in PubMed
• Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype Antimicrob Agents Chemother. 2022 10 18; 66(10):e0069522. . View in PubMed
• Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics Antimicrob Agents Chemother. 2022 02 15; 66(2):e0204621. . View in PubMed
• VP Shunt With Recurrent Malfunction in Two Pediatric Patients: Is the Hydrocephalus Truly Idiopathic? Pediatr Infect Dis J. 2022 04 01; 41(4):358-359.. View in PubMed
• Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia J Antimicrob Chemother. 2022 10 28; 77(11):2956-2959. . View in PubMed
• Pharmacokinetic modelling of caspofungin to develop an extended dosing regimen in paediatric patients J Antimicrob Chemother. 2022 07 28; 77(8):2209-2216. . View in PubMed
• Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients Pharmaceutics. 2021 Dec 16; 13(12). . View in PubMed
• Growth medium and nitric oxide alter Mycobacterium abscessus morphotype and virulence Microbiol Res. 2021 Dec; 253:126887. . View in PubMed
• A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy Pharmacol Res Perspect. 2021 10; 9(5):e00856. . View in PubMed
• Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia J Clin Pharmacol. 2021 06; 61(6):755-762. . View in PubMed
• ‘Cost-benefit analysis comparing trough, two-level AUC, and Bayesian AUC dosing for vancomycin’: authors’ reply Clin Microbiol Infect. 2021 06; 27(6):929-930. . View in PubMed
• Roger WJelliffe, MD, FCP, FAAPS: A World Leader in Population Pharmacokinetic and Pharmacodynamic Modeling and Model-Based Target Controlled Individualized Dosing. Clin Pharmacol Ther. 2021 01; 109(1):22-24. . View in PubMed
• Supporting Precision Dosing in Drug Labeling Clin Pharmacol Ther. 2021 01; 109(1):37-41. . View in PubMed
• Ther Drug Monit. 2021 08 01; 43(4):461-471. . View in PubMed
• Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression Antimicrob Agents Chemother. 2021 03 18; 65(4). . View in PubMed
• The Pharmacodynamic-Toxicodynamic Relationship of AUC and Cmax in Vancomycin-Induced Kidney Injury in an Animal Model Antimicrob Agents Chemother. 2021 02 17; 65(3). . View in PubMed
• The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens Antimicrob Agents Chemother. 2021 01 20; 65(2). . View in PubMed
• Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients Antimicrob Agents Chemother. 2021 07 16; 65(8):e0029021. . View in PubMed
• Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance Antimicrob Agents Chemother. 2021 06 17; 65(7):e0029321. . View in PubMed
• Editorial: In Memory of Roger Jelliffe, MD Ther Drug Monit. 2021 08 01; 43(4):459-460. . View in PubMed
• The case for precision dosing: medical conservatism does not justify inaction J Antimicrob Chemother. 2021 06 18; 76(7):1661-1665. . View in PubMed
• Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity Antimicrob Agents Chemother. 2021 05 18; 65(6). . View in PubMed
• Comment on: AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics J Antimicrob Chemother. 2021 08 12; 76(9):2486-2488. . View in PubMed
• Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships Antimicrob Agents Chemother. 2021 09 17; 65(10):e0106021. . View in PubMed
• Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase Antimicrob Agents Chemother. 2021 09 17; 65(10):e0069321. . View in PubMed
• An Algorithm for Nonparametric Estimation of a Multivariate Mixing Distribution with Applications to Population Pharmacokinetics Pharmaceutics. 2020 Dec 30; 13(1). . View in PubMed
• How to design a study to evaluate therapeutic drug monitoring in infectious diseases? Clin Microbiol Infect. 2020 Aug; 26(8):1008-1016.. View in PubMed
• Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime Clin Pharmacokinet. 2020 08; 59(8):1027-1036. . View in PubMed
• Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children Clin Pharmacokinet. 2020 08; 59(8):1049-1061. . View in PubMed
• Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate Clin Pharmacokinet. 2020 07; 59(7):885-898. . View in PubMed
• Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper Intensive Care Med. 2020 06; 46(6):1127-1153. . View in PubMed
• Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics Ther Drug Monit. 2020 02; 42(1):83-92. . View in PubMed
• Development and Implementation of Electronic Health Record-Integrated Model-Informed Clinical Decision Support Tools for the Precision Dosing of Drugs Clin Pharmacol Ther. 2020 01; 107(1):129-135. . View in PubMed
• In Memoriam: Roger Jelliffe, MD, FCP, FAAPS Ther Drug Monit. 2020 10 01; 42(5):658-659. . View in PubMed
• Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model Antimicrob Agents Chemother. 2020 08 20; 64(9). . View in PubMed
• Use of Simulation Strategies to Predict Subtherapeutic Meropenem Exposure Caused by Augmented Renal Clearance in Critically Ill Pediatric Patients With Sepsis J Pediatr Pharmacol Ther. 2020; 25(5):413-422. . View in PubMed
• Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing Antimicrob Agents Chemother. 2020 08 20; 64(9). . View in PubMed
• Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models? Antimicrob Agents Chemother. 2020 11 17; 64(12).. View in PubMed
• Development of a methodology to make individual estimates of the precision of liquid chromatography-tandem mass spectrometry drug assay results for use in population pharmacokinetic modeling and the optimization of dosage regimens PLoS One. 2020; 15(3):e0229873. . View in PubMed
• Building Optimal Three-Drug Combination Chemotherapy Regimens Antimicrob Agents Chemother. 2020 10 20; 64(11). . View in PubMed
• Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients Antimicrob Agents Chemother. 2020 08 20; 64(9). . View in PubMed
• Update in antibiotic therapy in intensive care unit: report from the 2019 Nîmes International Symposium Anaesth Crit Care Pain Med. 2019 12; 38(6):647-656. . View in PubMed
• Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis Ther Drug Monit. 2019 12; 41(6):719-725. . View in PubMed
• Development of Chronic Pseudomonas aeruginosa-Positive Respiratory Cultures in Children with Tracheostomy Lung. 2019 12; 197(6):811-817. . View in PubMed
• Optimizing Gentamicin Dosing in Pediatrics Using Monte Carlo Simulations Pediatr Infect Dis J. 2019 04; 38(4):390-395. . View in PubMed
• Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study Antimicrob Agents Chemother. 2019 04; 63(4). . View in PubMed
• Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children Bone Marrow Transplant. 2019 03; 54(3):448-457. . View in PubMed
• Early Use of Anti-influenza Medications in Hospitalized Children With Tracheostomy Pediatrics. 2019 03; 143(3). . View in PubMed
• In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae J Antimicrob Chemother. 2019 12 01; 74(12):3521-3529. . View in PubMed
• Length of Stay and Hospital Revisit After Bacterial Tracheostomy-Associated Respiratory Tract Infection Hospitalizations Hosp Pediatr. 2018 Jan 16. . View in PubMed
• Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model Antimicrob Agents Chemother. 2018 12; 62(12). . View in PubMed
• The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model Antimicrob Agents Chemother. 2018 12; 62(12). . View in PubMed
• Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs Clin Pharmacol Ther. 2018 11; 104(5):966-973. . View in PubMed
• Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology J Clin Pharmacol. 2018 10; 58 Suppl 10:S73-S85. . View in PubMed
• Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model Antimicrob Agents Chemother. 2018 08; 62(8). . View in PubMed
• Risk factors for hospitalizations due to bacterial respiratory tract infections after tracheotomy Pediatr Pulmonol. 2018 03; 53(3):349-357. . View in PubMed
• Pharmacokinetic/Pharmacodynamic Determinants of Vancomycin Efficacy in Enterococcal Bacteremia Antimicrob Agents Chemother. 2018 03; 62(3). . View in PubMed
• Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing Antimicrob Agents Chemother. 2018 02; 62(2). . View in PubMed
• Pharmacodynamics of teicoplanin against MRSA J Antimicrob Chemother. 2017 Dec 01; 72(12):3382-3389. . View in PubMed
• Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response Clin Infect Dis. 2017 Jun 01; 64(11):1557-1563. . View in PubMed
• Clin Pharmacol Ther. 2017 May; 101(5):646-656. . View in PubMed
• Is continuous infusion of imipenem always the best choice? Int J Antimicrob Agents. 2017 Mar; 49(3):348-354.. View in PubMed
• Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin Mol Cancer Res. 2017 12; 15(12):1704-1713. . View in PubMed
• Tools for the Individualized Therapy of Teicoplanin for Neonates and Children Antimicrob Agents Chemother. 2017 10; 61(10). . View in PubMed
• Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions Pediatr Pulmonol. 2017 09; 52(9):1212-1218. . View in PubMed
• A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics Clin Pharmacokinet. 2017 04; 56(4):435-447. . View in PubMed
• Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole¹ J Pharmacokinet Pharmacodyn. 2017 04; 44(2):95-111. . View in PubMed
• Correction for Rhodes et al, Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. Antimicrob Agents Chemother. 2017 04; 61(4). . View in PubMed
• Scalpels not hammers: The way forward for precision drug prescription Clin Pharmacol Ther. 2017 03; 101(3):368-372. . View in PubMed
• Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV) Sci Rep. 2017 10 31; 7(1):14421. . View in PubMed
• The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma Cancer Manag Res. 2017; 9:731-739. . View in PubMed
• Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation Front Pharmacol. 2017; 8:358. . View in PubMed
• Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones Expert Opin Drug Metab Toxicol. 2016 May; 12(5):533-44. . View in PubMed
• Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy Antimicrob Agents Chemother. 2016 Apr; 60(4):2336-42. . View in PubMed
• An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity J Infect Chemother. 2016 Feb; 22(2):78-83. . View in PubMed
• Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity? J Antimicrob Chemother. 2016 Feb; 71(2):484-9.. View in PubMed
• Dosage Adjustments Related to Young or Old Age and Organ Impairment J Clin Pharmacol. 2016 12; 56(12):1461-1473. . View in PubMed
• The Brief Case: Neonatal Meningitis Caused by Listeria monocytogenes Diagnosed by Multiplex Molecular Panel J Clin Microbiol. 2016 12; 54(12):2846-2849. . View in PubMed
• Closing the Brief Case: Neonatal Meningitis Caused by Listeria monocytogenes Diagnosed by Multiplex Molecular Panel J Clin Microbiol. 2016 12; 54(12):3075. . View in PubMed
• Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy J Antimicrob Chemother. 2016 11; 71(11):3168-3178. . View in PubMed
• Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats Antimicrob Agents Chemother. 2016 10; 60(10):5742-51. . View in PubMed
• A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients Ther Drug Monit. 2016 10; 38(5):593-9. . View in PubMed
• Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial J Antimicrob Chemother. 2016 08; 71(8):2234-40. . View in PubMed
• Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software Ther Drug Monit. 2016 06; 38(3):332-42. . View in PubMed
• Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1401-10. . View in PubMed
• Characterisation of a multidrug-resistant meningitic Escherichia coli strain (O75:K1:H5) isolated from an infant that is sensitive to memantine, a newly identified host-directed antimicrobial drug Int J Antimicrob Agents. 2015 Nov; 46(5):598-600. . View in PubMed
• Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients–A Prospective, Randomized Study Transplantation. 2015 Oct; 99(10):2158-66. . View in PubMed
• Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs Antimicrob Agents Chemother. 2015 Sep; 59(9):5181-9. . View in PubMed
• Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis J Antimicrob Chemother. 2015 Jul; 70(7):2068-73. . View in PubMed
• Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy J Clin Pharmacol. 2015 Jul; 55(7):798-808. . View in PubMed
• Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance Ther Drug Monit. 2015 Jun; 37(3):389-94. . View in PubMed
• Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia J Infect Dis. 2015 Apr 15; 211(8):1326-33. . View in PubMed
• Achieving target voriconazole concentrations more accurately in children and adolescents Antimicrob Agents Chemother. 2015; 59(6):3090-7. . View in PubMed
• Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients Antimicrob Agents Chemother. 2015; 59(6):2986-94. . View in PubMed
• Innovative approaches to optimizing the delivery of vancomycin in individual patients Adv Drug Deliv Rev. 2014 Nov 20; 77:50-7. . View in PubMed
• A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults Antimicrob Agents Chemother. 2014 Nov; 58(11):6735-41. . View in PubMed
• Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients Br J Clin Pharmacol. 2014 Oct; 78(4):836-46. . View in PubMed
• Population pharmacokinetics of a single intramuscular administration of tulathromycin in adult desert tortoises (Gopherus agassizii) J Vet Pharmacol Ther. 2014 Oct; 37(5):500-7. . View in PubMed
• Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans Neuroreport. 2014 Sep 10; 25(13):1018-23. . View in PubMed
• Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy Antimicrob Agents Chemother. 2014 Jul; 58(7):4094-102. . View in PubMed
• Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions Lancet Infect Dis. 2014 Jun; 14(6):498-509. . View in PubMed
• New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients Pediatr Transplant. 2014 Feb; 18(1):103-11. . View in PubMed
• Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women J Acquir Immune Defic Syndr. 2014 Jan 01; 65(1):72-7. . View in PubMed
• The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy Curr Pharm Des. 2014; 20(39):6191-206. . View in PubMed
• Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014; 58(1):309-16.. View in PubMed
• Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis PLoS One. 2014; 9(7):e101311. . View in PubMed
• Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa Antimicrob Agents Chemother. 2013 Dec; 57(12):5811-9. . View in PubMed
• NPEST: a nonparametric method and a database for transcription start site prediction Quant Biol. 2013 Dec; 1(4):261-271. . View in PubMed
• Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis Antimicrob Agents Chemother. 2013 Dec; 57(12):5854-9. . View in PubMed
• Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation Transpl Int. 2013 Dec; 26(12):1198-207. . View in PubMed
• Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents Pediatr Infect Dis J. 2013 Sep; 32(9):e370-6. . View in PubMed
• Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients J Infect Dis. 2013 Jul 15; 208(2):351-61. . View in PubMed
• Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian J Pharmacokinet Pharmacodyn. 2013 Apr; 40(2):189-99. . View in PubMed
• Software for dosage individualization of voriconazole for immunocompromised patients Antimicrob Agents Chemother. 2013 Apr; 57(4):1888-94. . View in PubMed
• Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Feb; 115(2):224-32. . View in PubMed
• From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine CPT Pharmacometrics Syst Pharmacol. 2012 Oct 03; 1:e9. . View in PubMed
• Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Oct; 114(4):480-6. . View in PubMed
• Antiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction J Clin Virol. 2012 Sep; 55(1):40-5. . View in PubMed
• Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R Ther Drug Monit. 2012 Aug; 34(4):467-76. . View in PubMed
• High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count Ther Drug Monit. 2012 Jun; 34(3):237-41. . View in PubMed
• Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals Antimicrob Agents Chemother. 2012 Jun; 56(6):2959-66. . View in PubMed
• More codeine fatalities after tonsillectomy in North American children Pediatrics. 2012 May; 129(5):e1343-7. . View in PubMed
• Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients Biol Blood Marrow Transplant. 2012 May; 18(5):731-8. . View in PubMed
• Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients Antimicrob Agents Chemother. 2012 Apr; 56(4):1862-9. . View in PubMed
• Obesity and its impact on drug therapy: are we ready for this change? Clin Pharmacokinet. 2011 Dec 01; 50(12):825-6.. View in PubMed
• Posaconazole for chronic refractory coccidioidal meningitis Clin Infect Dis. 2011 Dec; 53(12):1252-4. . View in PubMed
• Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients Curr Pharm Biotechnol. 2011 Dec; 12(12):2044-61. . View in PubMed
• Nonparametric population modeling and Bayesian analysis Pharmacol Res. 2011 Oct; 64(4):426. . View in PubMed
• Comment: assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients Ann Pharmacother. 2011 Sep; 45(9):1171-2. . View in PubMed
• CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children Ther Drug Monit. 2011 Aug; 33(4):417-24. . View in PubMed
• Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study J Adolesc Health. 2011 Jun; 48(6):637-40. . View in PubMed
• Increased clearance of morphine in sickle cell disease: implications for pain management J Pain. 2011 May; 12(5):531-8. . View in PubMed
• Pharmacokinetic optimization of antiretroviral therapy in children and adolescents Clin Pharmacokinet. 2011 Mar; 50(3):143-89. . View in PubMed
• Incidence and predictors of invasive candidiasis associated with candidaemia in children Mycoses. 2011 Mar; 54(2):146-53. . View in PubMed
• Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers Antimicrob Agents Chemother. 2010 Nov; 54(11):4619-25. . View in PubMed
• Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead AIDS Res Hum Retroviruses. 2010 Sep; 26(9):947-53. . View in PubMed
• Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician J Clin Pharmacol. 2010 Jul; 50(7):842-7. . View in PubMed
• Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit. 2010 Jun; 32(3):273-81.. View in PubMed
• Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children J Antimicrob Chemother. 2010 Apr; 65(4):808-9; author reply 809-10. . View in PubMed
• Voriconazole pharmacokinetics and pharmacodynamics in children Clin Infect Dis. 2010 Jan 01; 50(1):27-36. . View in PubMed
• Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children Antimicrob Agents Chemother. 2009 Jun; 53(6):2532-8. . View in PubMed
• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir Ther Clin Risk Manag. 2009 Jun; 5(3):595-615. . View in PubMed
• Pharmacokinetics and safety of caspofungin in older infants and toddlers Antimicrob Agents Chemother. 2009 Apr; 53(4):1450-6. . View in PubMed
• Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization J Clin Pharmacol. 2008 Sep; 48(9):1081-91. . View in PubMed
• Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy J Acquir Immune Defic Syndr. 2007 Jan 01; 44(1):38-42. . View in PubMed
• Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents Antimicrob Agents Chemother. 2005 Nov; 49(11):4536-45. . View in PubMed
• Management of antiretroviral therapy in neonates, children, and adolescents Curr HIV/AIDS Rep. 2004 Jun; 1(2):97-104. . View in PubMed
• Management of Antiretroviral Therapy in Neonates, Children, and Adolescents Curr Infect Dis Rep. 2003 Dec; 5(6):521-530. . View in PubMed
• Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission Afr Health Sci. 2003 Aug; 3(2):61-7. . View in PubMed
• Pharmacokinetic characteristics of caspofungin in two pediatric liver transplant patients Curr Ther Res Clin Exp. 2003 Feb; 64(2):127-36. . View in PubMed
• Organ heavy-metal accumulation during parenteral nutrition is associated with pathologic abnormalities in rats Nutrition. 2001 Jul-Aug; 17(7-8):600-6. . View in PubMed
• Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time Pediatrics. 2001 Feb; 107(2):404-5. . View in PubMed
• Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycinClin Microbiol Infect. 2021 Sep; 27(9):1346. e1-1346. e7. . View in PubMed

• Klausner, Jeffrey